Adaptive Biotechnologies plans separation of immune medicine platform

Adaptive Biotechnologies

15/06/2026 21:44

    June 15 (Reuters) - Adaptive Biotechnologies  ADPT.O  said
on Monday it planned to separate its immune medicine business
from its residual cancer-testing unit, as it reviews options for
the drug-discovery business and focuses on testing.
    * The company said it was reviewing options for the immune
medicine business and expected to choose a preferred path by the
end of 2026.
    * Adaptive's immune medicine platform helps conduct drug
research by identifying therapeutic targets, and accelerate the
development of precision medicines. 
    * Adaptive said the residual cancer-testing unit, which
includes its clonoSEQ test, had reached profitability and
expanded insurance coverage.
    * ClonoSEQ is used to detect small traces of cancer that may
remain after treatment and is also used in drug-development
studies.
    * The unit's revenue rose to $212 million in 2025 from $103
million in 2023, the company said.
    * Adaptive said the immune medicine business might be better
placed outside the company's diagnostics-focused model.
    * The company said there was no assurance the review would
result in a deal or any other outcome. 


 (Reporting by Kunal Das in Bengaluru; Editing by Anil D'Silva)
 ((Kunal.Das2@thomsonreuters.com;))